+A -A

Comparative View:

3Q16 Create chart
Net sales revenues 967,090
Change in Fair Value of Biological Assets 38,403
Cost of Goods Sold -605,192
Depreciation / Amortization / exhaustion -102,906
Exhaustion of biological assets -28,219
Gross Profit 269,176
Selling Expenses -150,441
General and Administrative Expenses -33,739
Management Compensation -3,476
Other Operating Compensation 32,495
Equity income from subsidiaries 0
Operating Profit before Financial Income and Equity 114,015
Financial Income 49,897
Financial Expenses -122,537
Income Before Income Tax and Social Contribution 41,375
Income and social contribution taxes - current -10,922
Income Tax and Social Contribution - Deferred -598
Effect profit from discontinued operation null
Net Income 29,855
Recurring Net Income 9,404
Recurring EBITDA 185,908
EBITDA Margin 19.2 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza